Pulmonology News

The FDA announced it has authorized the marketing of 20 Zyn nicotine pouch products, citing their greater health benefits vs. cigarettes and other tobacco products.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

As wildfires continue to spread across the Los Angeles area, residents with asthma and other respiratory diseases face increased risks to their health.

Entering 2025, adults with moderate to severe obstructive sleep apnea and obesity have a new FDA-approved treatment option that takes the form of a GIP/GLP-1 dual agonist, according to a press release from Eli Lilly and Company.

Among individuals aged at least 12 years with cystic fibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor was similar or better than Trikafta depending on the endpoint, according to results published in The Lancet Respiratory Medicine.

The FDA has proposed limiting the level of nicotine in cigarettes and other combusted tobacco products like cigars and pipe tobacco to make them “minimally or nonaddictive,” according to a press release from the agency.

Integrated care involving medication and intensive counseling showed effectiveness for smoking cessation among adults undergoing screening for lung cancer, the results of a randomized clinical trial showed.

As physicians, we have all borne witness to patients dying at a young age, whether from an unforeseen illness or injury.

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, lorundrostat, in adults with obstructive sleep apnea and hypertension, according to a press release.